COX-2 inhibitors: increased risk of CV events?

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2001年 / 867卷 / 1期
关键词：
Celecoxib; Naproxen; Rofecoxib; Nabumetone; Adverse Event Reporting System;
D O I：
10.2165/00128415-200108670-00001
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [21] COX-2 inhibitors
    Brooks, PM
    Day, RO
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2000, 173 (08) : 433 - 436
  • [22] Increased COX-2 selectivity of NSAIDs appears to be associated with increased cardiovascular (CV) risks
    [J]. Reactions Weekly, 2006, 1119 (1) : 5 - 5
  • [23] COX-2 inhibitors
    Seidenberg, BC
    [J]. LANCET, 1999, 353 (9168): : 1978 - 1978
  • [24] COX-2 inhibitors
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (03) : 122 - 123
  • [25] COX-2 inhibitors
    Becker, RC
    [J]. TEXAS HEART INSTITUTE JOURNAL, 2005, 32 (03): : 380 - 383
  • [26] COX-2 inhibitors
    Hawkey, CJ
    [J]. LANCET, 1999, 353 (9149): : 307 - 314
  • [27] COX-2 inhibitors
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 1997, 2 (09) : 393 - 393
  • [28] COX-2 inhibitors
    Lawrie, MM
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (07) : 367 - 367
  • [29] Disruption of cholesterol transport by celecoxibb and COX-2 silencing: A potential mechanism of increased cardiovascular (CV) risk
    Edelman, Sari D.
    Anwar, Kamran
    Chan, Edwin S.
    Wirkowski, Peter
    Morano, Jacqueline
    Carsons, Steven E.
    Reiss, Allison B.
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (12): : 4244 - 4244
  • [30] Natriuretic response to increased pressure is preserved with COX-2 inhibitors
    Gross, JM
    Dwyer, JE
    Knox, FG
    [J]. HYPERTENSION, 1999, 34 (05) : 1163 - 1167
12345